You are viewing the site in preview mode
Skip to main content
|
Chemotherapy regimen
|
Total n = 96
|
Complying group n = 58
|
Non-complying group n = 38
|
|---|
|
5-flourouracil
|
1
|
1
|
0
|
|
ABVD
|
2
|
0
|
2
|
|
AC
|
7
|
6
|
1
|
|
Bendamustine
|
3
|
0
|
3
|
|
B-mab+CBDCA+PAC
|
1
|
1
|
0
|
|
B-mab+mFOLFOX6
|
3
|
2
|
1
|
|
CBDCA+GEM
|
2
|
2
|
0
|
|
CBDCA+VP16
|
2
|
2
|
0
|
|
CHOP
|
5
|
1
|
4
|
|
DeVIC
|
2
|
1
|
1
|
|
DOC
|
2
|
0
|
2
|
|
DOXIL
|
2
|
2
|
0
|
|
GC
|
1
|
1
|
0
|
|
GEM
|
12
|
12
|
2
|
|
High dose-AraC
|
2
|
0
|
2
|
|
Hign dose MTX
|
2
|
0
|
2
|
|
Irinotecan
|
2
|
2
|
0
|
|
Pemetrexed + CBDCA
|
3
|
3
|
0
|
|
Pemetrexed
|
1
|
1
|
0
|
|
PAC+GEM
|
2
|
2
|
0
|
|
R-CHOP
|
3
|
0
|
3
|
|
Rituximab
|
1
|
1
|
0
|
|
R-THPCOP
|
10
|
4
|
6
|
|
S1+DOC
|
2
|
2
|
0
|
|
S1+CDDP
|
1
|
1
|
0
|
|
S1+GEM
|
8
|
6
|
2
|
|
SOX
|
4
|
1
|
3
|
|
THPCOP
|
2
|
0
|
2
|
|
VNR + HER
|
1
|
0
|
1
|
|
CBDCA+PAC
|
1
|
1
|
0
|
|
Weekly PAC
|
1
|
1
|
0
|
|
Weekly PAC+ HER
|
2
|
1
|
1
|
- ABVD: doxorubicin+ bleomycin+ vincristine+ dacarbazine, B-mab: bevacizumab, CBDCA: carboplatin, PAC: paclitaxel mFOLFOX 6: 5-fluorouracil+ levofolinate+ oxaliplatin, DOC: docetaxel, GEM: gemcitabine, VP16: etoposide, CHOP: cyclophosphamide+ doxorubicin+ vincristine + predonizorne, DeVIC: carboplatin+etoposide+ifosfamide, GC: emcitabine+ cisplatin, AraC: cytarabine, MTX: methotrexate, R: rituximab, THPCOP: rituximap+cyclophosphamide+pirarubicin+vincristine + Predonizorne, S1: Tegafur+ gimeracil+ oteracil, CDDP: cisplatin, SOX: S1+ oxaliplaton, VNR: vinorelbine, HER: trastuzumab.
